D.T.I.C

Indication of D.T.I.C:

Darcarbazine is used in the treatment of the following tumours: - Metastatic malignant melanoma- Ewings sarcoma- Rhabdomyosarcoma - Hodgkins disease

Action of D.T.I.C:

Dacarbazine interferes with cellular replication by forming cross-linkages between DNA strands.

Dose Advice of D.T.I.C:

Specialist protocols should be consulted concerning dosages: Melanoma: - An initial dose that may be used is 250 mg/m2 daily given by intravenous infusion on days 1-5 of each 21-day cycle. - Alternatively, 800 mg/m2 can be given on day 1 of each 21-day cycle.- These doses may be used in single or combination therapy.- Subsequent doses depend on the individual patients response and the severity of adverse effects.Hodgkins disease: - Dacarbazine is used in combination treatment with other antineoplastic agents.- 150 mg/m2 each day given by intravenous infusion on days 1?5 of each 28-day cycle.- Alternatively, 375 mg/m2 can be given on day 1 and day 15 of each 28-day cycle.

Schedule of D.T.I.C:

S4

Common side effects of D.T.I.C:

- Bone marrow suppression- Nausea- Vomiting- Diarrhoea- Fever- Muscle aches- Fatigue- Facial flushing- Pain along the injected vein

Uncommon side effects of D.T.I.C:

- Low white cell count- Blurred vision- Hair loss- Confusion- Headache- Rash- Increased sensitivity of skin to light- Seizures

Diseases treated by D.T.I.C:

Hodgkins Lymphoma

• D.t.i.c
• Dacarbazine for injection

• Blenamax
• Blenoxane
• D.t.i.c
• Dacarbazine for injection
• Natulan
• Oncovin